Role of Interleukin-13 in Asthma
- 12 September 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Allergy and Asthma Reports
- Vol. 13 (5), 415-420
- https://doi.org/10.1007/s11882-013-0373-9
Abstract
Interleukin-13 is a pleiotropic TH2 cytokine that has been shown to be central to the pathogenesis of asthma. Some of the most prominent of the effects of IL-13 include increases in goblet cell differentiation, activation of fibroblasts, elevation of bronchial hyperresponsiveness, and switching of B cell antibody production from IgM to IgE. The relevances of these effects to asthma have been carefully studied in both animal models and more recently in human studies. As the role of IL-13 in asthma has become more defined, a number of potential biomarkers for TH2 airway inflammation, and hence IL-13 activity, have been identified, including blood and sputum eosinophils, total serum IgE, proteins derived from the bronchial epithelium (e.g., serum periostin), and exhaled nitric oxide. Most importantly, many of these markers for TH2 inflammation are strong predictors for positive responses to inhaled corticosteroid treatment. These biomarkers may also be useful in identifying patients who are most likely to benefit from specific IL-13 antagonism, as was demonstrated in a recent clinical trial of anti-IL-13 antibody therapy (lebrikizumab) in patients with poorly controlled asthma despite using inhaled corticosteroids. In that study, significant improvements in FEV1 were observed in patients with elevations of serum periostin but not in patients with normal periostin levels. These data indicate that IL-13 antagonists may fulfill an important unmet need in patients with poorly controlled asthma and biologic evidence of persistent IL-13 activity.Keywords
This publication has 48 references indexed in Scilit:
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regionsJournal of Allergy and Clinical Immunology, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The cytokine interleukin-33 mediates anaphylactic shockProceedings of the National Academy of Sciences of the United States of America, 2009
- Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthmaThorax, 2007
- Association between first‐degree familial predisposition of asthma and atopy (total IgE) in newbornsClinical and Experimental Allergy, 2006
- Exhaled nitric oxide correlates with airway eosinophils in childhood asthmaThorax, 2002
- Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthmaJournal of Allergy and Clinical Immunology, 2001